Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Fulgent Genetics, Inc. reported revenue of $323M, up 13.8% year over year. Operating margin was -28.2% and net margin -18.8%, on a free-cash-flow margin of -38.5% with capital expenditure at 7.0% of revenue. Every figure is computed directly from FLGT's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $323M | -28.2% | -18.8% |
| FY2024 | $283M | -26.1% | -15.1% |
| FY2023 | $289M | -67.6% | -58.0% |
| FY2022 | $619M | 28.8% | 23.2% |
| FY2021 | $993M | 68.1% | 51.1% |
How does FLGT compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AACG · ABSI · ACCS · ACHC · ACM · ADUS
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.